

Stratégies antihyperalgésiques périopératoires et Effets sur les douleurs chroniques postopératoires

Mise au point en 2015

Philippe Richebé, M.D., Ph.D.,

Professeur Agrégé


Département d'Anesthésiologie

Université of Montréal

Hôpital Maisonneuve-Rosemont

philipperichebe@live.com







North America





Seattle : 2008-2014



Montreal : 2014-présent

Disclosures

- Grants from:
 - INSERM, France
 - Universite de Bordeaux, France
 - SFAR
 - SFETD
 - Compagnies Pharmaceutiques (Investigator Initiated Research Grants) en France, USA, Canada: Air Liquide, Biocodex, Cadence Pharmaceuticals, Pfizer, Medasense LTD
 - National Institute for Health research (NIH)
 - The Department of Anesthesiology at UWMC, Seattle
 - The University of Washington, Seattle
- I have no financial interest in any of the companies above mentioned

Definition PPSP

(PPSP = Persistent PostSurgical Pain)

Les PPSP ont été définies par la “International Association for the Study of Pain (IASP)” comme un discomfort clinique qui dure depuis plus de deux mois après chirurgie.

Incidence

Chronic Pain as an Outcome of Surgery

A Review of Predictive Factors

Anesthesiology 2000; 93:1123-33

Frederick M. Perkins, M.D.,* Henrik Kehlet, M.D., Ph.D.†

Persistent postsurgical pain: risk factors and prevention

Henrik Kehlet, Troels S Jensen, Clifford J Woolf

Lancet 2006; 367: 1618-25

	Estimated incidence of chronic pain	Estimated chronic severe (disabling) pain (>5 out of score of 10)	US surgical volumes (1000s)†
Amputation ²	30-50%	5-10%	159 (lower limb only)
Breast surgery (lumpectomy and mastectomy) ³	20-30%	5-10%	479
Thoracotomy ⁴⁻⁷	30-40%	10%	Unknown
Inguinal hernia repair ⁸⁻¹⁰	10%	2-4%	609
Coronary artery bypass surgery ¹¹⁻¹³	30-50%	5-10%	598
Caesarean section ¹⁴	10%	4%	220

- Schug et al., 2012: prévalence PPSP:
 - Reduction de 40% a 18% si on ne prend en compte que les douleurs de plus de 3/10 dans la zone de la chirurgie
 - Seulement 6% si on exclut tous les patients qui avaient déjà des douleurs chroniques dans la zone opérée avant la chirurgie

The neuropathic component in persistent postsurgical pain: A systematic literature review ☆

PAIN® 154 (2013) 95–102

Simon Haroutiunian ^{a,*}, Lone Nikolajsen ^{a,b}, Nanna Brix Finnerup ^a, Troels Staehelin Jensen ^{a,c}

281 studies that investigated PPSP after 11 types of surgery. The prevalence of PPSP in each surgical group was examined. The prevalence of NeuP was determined by applying the recently published NeuP probability grading system. The prevalence of probable or definite NeuP was high in patients with persistent pain after thoracic and breast surgeries—66% and 68%, respectively. In patients with PPSP after groin hernia repair, the prevalence of NeuP was 31%, and after total hip or knee arthroplasty it was 6%.

Neuropathic Aspects of Persistent Postsurgical Pain: A French Multicenter Survey With a 6-Month Prospective Follow-Up

Christian Dualé, ^{*,†,‡} Lemlih Ouchchane, ^{§,||,¶} Pierre Schoeffler, ^{‡,§,*,**} the EDONIS Investigating Group¹, and Claude Dubray ^{*,†,‡,§}

The Journal of Pain, Vol 15, No 1 (January), 2014

at the third and sixth months after surgery. In the 2,397 patients who completed follow-up, the cumulative risk of N-PSPP within the 6 months ranged from 3.2% (laparoscopic herniorrhaphy) to 37.1% (breast cancer surgery).

Facteurs de Risque et Spécificités de Populations



Facteurs de Risque

- Les facteurs de risque classiques :
 - Douleur préopératoire
 - Consommation d'analgésique préopératoire importante,
 - Et haut niveaux de douleur postopératoire
- Corrélation entre PPSP et le degré préopératoire de :
 - “Catastrophizing” (tendance à exagérer le pessimisme sur le devenir),
 - Anxiété,
 - Peur de la chirurgie et de la Douleur PostOp (DPO),
 - Absence de support dans l'environnement du patient,
 - Et/ou réponse exagérée au stimuli expérimentaux (quantitative sensory testing: QSTs)

Facteurs de Risque

- Variations dues à la génétique :
 - COMT (catecholamine-O-methyl-transferase) polymorphisme : est associé avec des variations de sensibilité à la douleur
 - melanocortin-1 receptor gene polymorphisme : chez les femmes rousses, est associé à une plus haute réponse à certains opioïdes
 - Cependant aucun “single nucleotide polymorphism” (SNP) n’a été réellement corrélé avec le risque de développer des PPSP

Correlation entre Hyperalgésies Précoces et PPSP





Lavand'homme P, Current opinion in Anesthesiology 2006
Eisenach J, RAPM 2006

“Hyperalgésie”

Acta Anaesthesiol Scand. 1997 Oct;41(9):1124-32.

Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery.


Stubhaug A, Breivik H, Eide PK, Kreunen M, Foss A.




Pathophysiologie du développement des PPSP

- trauma chirurgical
- absence d'analgésie multimodale

A- Influx nociceptifs



Sensibilisation périphérique
et centrale _ lésion nerveuse




B- Opioides

- hautes doses d'opioïdes intraopératoires
- absence de stratégies anti-sensibilisantes



« PPSP »

Sensibilisation périphérique




Costigan M. and Woolf C.J. The Journal of Pain, 2000

Sensibilisation centrale




Sensibilisation centrale




Ji RR et al, Trends in Neurosciences 2003


A - Phosphorylation



B - Trafficking




C - Transcription




Latremoliere and Woolf J Pain 2009


Récepteurs NMDA



Krystal et al, Pharmacol. Ther., 2003



Opioid Induced Hyperalgesia OIH



Opioid Induced Hyperalgesia

D₁



No Fentanyl

Fentanyl

p-p38


p-CamKII

Saline -Incision

Saline -Incision

Fentanyl-Incision

Fentanyl-Incision




Saline Fentanyl Saline Fentanyl
Incision Incision Incision Incision



BDNF



Beta-Actin

Rivat, Richebe, in progress




Richebe et al. 2012

Opioid Induced Hyperalgesia



**In vivo Ephy on WDR neurons,
rats treated with fentanyl + GA +
Incision**






**"Incised" Rats under GA without
fentanyl**

Intravenous Infusion of Remifentanyl Induces Transient Withdrawal Hyperalgesia Depending on Administration Duration in Rats

Ryosuke Ishida, MD,* Tetsuro Nikai, MD,* Tatsuya Hashimoto, MD, PhD,* Toshiko Tsumori, PhD,† and Yoji Saito, MD, PhD*

(Anesth Analg 2012;114:224–9)





Approche pratique en Anesthésie

Opioid-Induced Hyperalgesia (OIH)

chez l'homme?

Premières études...

Intraoperative high dose fentanyl induces postoperative fentanyl tolerance

- Induction: 1 versus 15mcg/kg IV fentanyl
- Maintenance: 0 versus 100mcg/h




FIGURE 1 Postoperative visual analogue scores (VAS) (mean $\pm$ SD) during the first postoperative 16 hr. *: $P < 0.05$.




FIGURE 2 Postoperative accumulated fentanyl consumption (μ g) (mean $\pm$ SD) during the first 16 hours after surgery. *: $P < 0.05$.

Remifentanyl-induced Postoperative Hyperalgesia and Its Prevention with Small-dose Ketamine



Vincent Joly, M.D.,* Philippe Richebe, M.D.,† Bruno Guignard, M.D.,* Dominique Fletcher, M.D.,‡ Pierre Maurette, M.D.,§ Daniel I. Sessler, M.D.,|| Marcel Chauvin, M.D.#

	Small-dose Remifentanyl (n = 25)	Large-dose Remifentanyl (n = 25)	Large-dose Remifentanyl- Ketamine (n = 24)
Remifentanyl dose, mg	0.9 ± 0.3*	6.7 ± 3.1	6.5 ± 3.4
Desflurane, MAC/h	0.8 ± 0.2*	0.5 ± 0.2	0.6 ± 0.2
Ephedrine, No. of doses/No. of patients	9/17	10/13	50/15†
Final intraoperative temperature, °C	36.6 ± 0.7	36.3 ± 0.8	36.3 ± 0.9
Awakening time, min	14 ± 6	13 ± 5	14 ± 6
Extubation time, min	16 ± 6	14 ± 6	15 ± 4
Time to first postoperative morphine, min	35 (28-46)	24 (20-33)	41 (32-52)
Morphine given in PACU, mg	16 (10-24)	20 (17-27)	20 (14-23)
0-48 h cumulative postoperative morphine consumption, mg	68 (50-91)	86 (59-109)‡	62 (48-87)
Postoperative nausea and vomiting, No. of patients	7	8	8
Droperidol, No. of doses/No. of patients	8/7	8/8	8/8

Remifentanyl
0.05 mcg/kg/min
VS
0.4 mcg/kg/min



**Abaissement seuil
nociceptif**



**Augmentation des
aires d'hyperalgésie**

Joly, Richebé et al, Anesthesiology 2005

Lien entre doses d'opioïdes intraop. et PPSP

Remifentanyl during cardiac surgery is associated with chronic thoracic pain 1 yr after sternotomy

120 patients, thoracotomies, évaluation précoce et à 1 an


Table 5 Association between the intraoperative total dose of remifentanyl and the remifentanyl dose corrected for LBM and duration of surgery, and OR for chronic thoracic pain 1 yr after cardiac surgery. LBM, lean body mass

	No chronic pain (n=72)	Chronic pain (n=18)	Odds ratio	95% CI	P-value	P-value for trend
Total dose of remifentanyl during surgery (mg) [n (%)]						
0	35 (49)	3 (17)	1		0.04	0.01
>0 and <1.7	19 (26)	6 (33)	3.68	0.8-16.4		
≥1.7	18 (25)	9 (50)	5.83	1.4-24.3		
Remifentanyl [$\mu\text{g (kg LBM)}^{-1} (\text{minute of surgery})^{-1}$] [n (%)]						
0	35 (49)	3 (17)	1		0.02	0.005
>0 and <0.12	19 (26)	5 (28)	3.07	0.7-14.3		
≥0.12	18 (25)	10 (55)	6.48	1.6-26.5		


Solutions pratiques quotidiennes

- trauma chirurgical
- absence d'analgésie multimodale

A- Influx nociceptifs



Sensibilisation périphérique
et centrale _ lésion nerveuse



B- Opioides

- hautes doses d'opioïdes intraopératoires
- absence de stratégies anti-sensibilisantes

« PPSP »

1/ Anesthésie Régionale

a) pour limiter les opioïdes intraop.

b) pour bloquer la sensibilisation à la douleur








Intraoperative Epidural Analgesia Combined with Ketamine Provides Effective Preventive Analgesia in Patients Undergoing Major Digestive Surgery

Patricia Lavand'homme, M.D., Ph.D.,* Marc De Kock, M.D., Ph.D.,† Hilde Waterloos, R.N.‡



819



Postop hyperalgesia = Postop CHRONIC PAIN



Different Anesthetic Techniques Associated with Different Incidences of Chronic Post-thoracotomy Pain: Low-Dose Remifentanyl Plus Presurgical Epidural Analgesia is Preferable to High-Dose Remifentanyl with Postsurgical Epidural Analgesia

Brussels, Belgium.

Interventions: High-dose remifentanyl (average effect-site concentration 5.61 ± 0.84 ng/mL) with epidural analgesia started and at the end of surgery or low-dose remifentanyl (average effect site concentration 1.99 ± 0.02 ng/mL) with epidural analgesia with 0.5% ropivacaine started at the beginning of anesthesia.



	High-Dose Group N = 20	Low-Dose Group N = 18	RR [95% CI]	p Value
1 month postop	16 (80%)	12 (66.7%)	1.2 [0.81-1.78]	0.364
3 months postop	15 (75%)	5 (27.8%)	2.7 [1.23-5.93]	0.013
6 months postop	16 (80%)	5 (27.8%)	2.9 [1.32-6.26]	0.008
End of study	14 (70%)	3 (16.7%)	4.2 [1.44- 12.27]	0.009

Salengros JC et al, JCVA 2010

De plus,


Liu SS et al., Int Orthop 2012 (acute pain)

And Liu SS et al., RAPM 2012 (chronic pain)

- 1) AG versus bloc neuraxial central = facteur de risque pour plus de douleurs aiguës après chirurgie de hanche et genoux :
 - OR 8.5 pour douleur au repos
 - OR 9.0 pour douleur durant l'activité
- 2) AG augmente le risque de PPSP à un an de la chirurgie : OR of 2.5


**2/ Donner moins
d'opioïdes intraop.**

Variations des stimuli durant anesthésie...



(from GLASS et coll.)

Interaction opioïdes et hypnotiques







Acute Opioid Tolerance

Intraoperative Remifentanyl Increases Postoperative Pain and Morphine Requirement

Bruno Guignard, M.D.,* Anne Elisabeth Bossard, M.D.,† Carole Coste, M.D.,‡ Daniel I. Sessler, M.D.,§ Claude Lebrault, M.D.,* Pascal Alfonsi, M.D.,* Dominique Fletcher, M.D.,* Marcel Chauvin, M.D.||





Remifentanyl-induced Postoperative Hyperalgesia and Its Prevention with Small-dose Ketamine

Vincent Joly, M.D.,* Philippe Richebe, M.D.,† Bruno Guignard, M.D.,* Dominique Fletcher, M.D.,‡ Pierre Maurette, M.D.,§ Daniel I. Sessler, M.D.,|| Marcel Chauvin, M.D.#

	Small-dose Remifentanyl (n = 25)	Large-dose Remifentanyl (n = 25)	Large-dose Remifentanyl- Ketamine (n = 24)
Remifentanyl dose, mg	0.9 ± 0.3*	6.7 ± 3.1	6.5 ± 3.4
Desflurane, MAC/h	0.8 ± 0.2*	0.5 ± 0.2	0.6 ± 0.2
Ephedrine, No. of doses/No. of patients	9/17	10/13	50/15†
Final intraoperative temperature, °C	36.6 ± 0.7	36.3 ± 0.8	36.3 ± 0.9
Awakening time, min	14 ± 6	13 ± 5	14 ± 6
Extubation time, min	16 ± 6	14 ± 6	15 ± 4
Time to first postoperative morphine, min	35 (28-46)	24 (20-33)	41 (32-52)
Morphine given in PACU, mg	16 (10-24)	20 (17-27)	20 (14-23)
0-48 h cumulative postoperative morphine consumption, mg	68 (50-91)	86 (59-109)‡	62 (48-87)
Postoperative nausea and vomiting, No. of patients	7	8	8
Droperidol, No. of doses/No. of patients	8/7	8/8	8/8



Nociceptive threshold is lowered



Area of Hyperalgesia is bigger


Joly, Richebé et al, Anesthesiology 2005

PhysioDoloris: a monitoring device for Analgesia / Nociception balance evaluation using Heart Rate Variability analysis.

R. Logier¹, M. Jeanne^{1, 2}, J. De jonckheere¹, A. Dassonneville¹, M. Delecroix², B. Tavernier²

¹INSERM CIC-IT 807, University Hospital of Lille, Institut Hippocrate, 2 avenue Oscar Lambret, 59037 LILLE Cedex, France


²Clinique d'Anesthésie Réanimation, University Hospital of Lille, H. Salengro, 2 avenue Oscar Lambret, 59037 LILLE Cedex, France



Mieux Monitorer




Mieux Monitorer





3/ Traitements Spécifiques

Sensibilisation Centrale



Ketamine

(Antagoniste des rec. NMDA)

Ketamine en anesthésie chez l'homme



Anesthesiology 2005; 103:147-55

© 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

Remifentanyl-induced Postoperative Hyperalgesia and Its Prevention with Small-dose Ketamine

Vincent Joly, M.D.,* Philippe Richebé, M.D.,† Bruno Guignard, M.D.,* Dominique Fletcher, M.D.,‡ Pierre Maurette, M.D.,§ Daniel I. Sessler, M.D.,|| Marcel Chauvin, M.D.#

	Small-dose Remifentanyl (n = 25)	Large-dose Remifentanyl (n = 25)	Large-dose Remifentanyl- Ketamine (n = 24)
Remifentanyl dose, mg	0.9 ± 0.3*	6.7 ± 3.1	6.5 ± 3.4
Desflurane, MAC/h	0.8 ± 0.2*	0.5 ± 0.2	0.6 ± 0.2
Ephedrine, No. of doses/No. of patients	9/17	10/13	50/15†
Final intraoperative temperature, °C	36.6 ± 0.7	36.3 ± 0.8	36.3 ± 0.9
Awakening time, min	14 ± 6	13 ± 5	14 ± 6
Extubation time, min	16 ± 6	14 ± 6	15 ± 4
Time to first postoperative morphine, min	35 (28-46)	24 (20-33)	41 (32-52)
Morphine given in PACU, mg	16 (10-24)	20 (17-27)	20 (14-23)
0-48 h cumulative postoperative morphine consumption, mg	68 (50-91)	86 (59-109)‡	62 (48-87)
Postoperative nausea and vomiting, No. of patients	7	8	8
Droperidol, No. of doses/No. of patients	8/7	8/8	8/8



Joly, Richebé et al, Anesthesiology 2005

Ketamine and postoperative pain – a quantitative systematic review of randomised trials

Nadia Elia*, Martin R. Tramèr

Pain 113 (2005) 61–70

EBCAP Institute (Evidence-Based Critical care, Anaesthesia and Pain treatment), Division of Anaesthesiology, Geneva University Hospitals, 24 Rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland

Received 5 May 2004; received in revised form 10 September 2004; accepted 28 September 2004

Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review)

*Acta Anaesthesiol Scand 2005; 49: 1405–1428
Printed in UK. All rights reserved*

R. F. BELL¹, J. B. DAHL², R. A. MOORE³ and E. KAISO⁴

¹Pain Clinic, Department of Anaesthesia and Intensive Care, Haukeland University Hospital and Department of Surgical Sciences, University of Bergen, Norway, ²Department of Anaesthesia and Intensive Care, Glostrup University Hospital, Glostrup, Denmark, ³Pain Research, Nuffield Department of Anaesthetics, University of Oxford, Oxford Radcliffe Hospitals, The Churchill, Oxford, UK and ⁴Pain Clinic, Department of Anaesthesia and Intensive Care Medicine, Helsinki University Central Hospital, Helsinki, Finland

Ketamine for Perioperative Pain Management

Sabine Himmelseher, M.D.,* Marcel E. Durieux, M.D., Ph.D.†



Anesthesiology 2005; 102:211–20

etc....



A systematic review of intravenous ketamine for postoperative analgesia

Kevin Laskowski, MD • Alena Stirling, MD •
William P. McKay, MD • Hyun J. Lim, MD

Can J Anesth/J Can Anesth (2011) 58:911–923



Ketamine in humans and Chronic Pain



De Kock M. and al.
Pain, 2001. 92: 373-80

A systematic review and meta-analysis of ketamine for the prevention of persistent post-surgical pain

E. D. McNicol¹, R. SCHUMANN² and S. HAROUTOUNIAN³

¹Department of Anesthesiology and Pharmacy, Tufts Medical Center, Boston, MA, USA, ²Department of Anesthesiology, Tufts Medical Center, Boston, MA, USA and ³Department of Anesthesiology, Washington University in St Louis, St Louis, MO, USA

Acta Anaesthesiol Scand 2014; 58: 1199–1213






Fig. 3. Forest plot of comparison: Incidence of persistent post-surgical pain: ketamine vs. placebo, outcome: incidence at 3 months, intravenous studies only. M-H, Mantel-Haenszel; CI, confidence interval.

Protoxyde d'azote (N₂O)

N₂O chez le rat...: un autre NMDA antagoniste


Decreases postop HA and Acute Morphine Tolerance



Collaboration avec W. Koppert

Erlangen – Nürnberg University

Germany



Richebé et al, in preparation

Avoidance of Nitrous Oxide for Patients Undergoing Major Surgery

the ENIGMA Trial Group

A Randomized Controlled Trial

Paul S. Myles

Anesthesiology 2007; 107:221-31

Conclusions: Avoidance of nitrous oxide and the concomitant increase in inspired oxygen concentration decreases the incidence of complications after major surgery, but does not significantly affect the duration of hospital stay. The routine use of nitrous oxide in patients undergoing major surgery should be questioned.

Chronic postsurgical pain after nitrous oxide anesthesia

PAIN[®] 152 (2011) 2514–2520

Matthew T.V. Chan^{a,*}, Alex C.M. Wan^a, Tony Gin^a, Kate Leslie^{b,c}, Paul S. Myles^{d,e}

Factors associated with mild-to-moderate chronic postsurgical pain.

Factors	Patients (n)	Patients with severe chronic postsurgical pain	Univariate OR (95% CI)	P Value	Multivariate OR (95% CI)	P Value
Age (y)	423	62.4 ± 12.5 (n = 46)	1.01 (0.99–1.05)	.24		
Gender						
Male	235	23 (9.8%)	Reference			
Female	188	23 (12.2%)	1.29 (0.69–2.37)	.44		
Wound type						
Others	199	17 (7.6%)	Reference			
Supraumbilical wound	224	29 (14.6%)	2.08 (1.10–3.91)	.03		
Wound length (cm)	423	19.3 ± 3.7 (n = 46)	1.17 (1.10–1.25)	.01	1.14 (1.04–1.26)	0.04
Minimally invasive surgery						
No	363	44 (12.1%)	Reference			
Yes	60	2 (3.3%)	0.25 (0.06–1.00)	.05		
Regional block						
No	352	42 (11.9%)	Reference			
Yes	71	4 (5.6%)	0.44 (0.15–1.27)	.08		
Severe acute postoperative pain						
No	378	26 (6.9%)	Reference			
Yes	45	20 (44.4%)	10.8 (5.32–22.0)	<.001	9.10 (2.58–32.1)	0.001
Anxiety ^a	423	11 (2–17) (n = 46)	2.38 (1.92–2.94)	<.001	2.28 (1.76–2.95)	<.001
Wound infection						
No	365	28 (7.7%)	Reference			
Yes	58	18 (31.0%)	5.42 (2.75–10.7)	.001	4.80 (1.48–15.6)	0.01
Nitrous oxide administration						
No	209	31 (14.8%)	Reference			
Yes	214	15 (7.0%)	0.43 (0.23–0.83)	.01	0.48 (0.33–0.93)	0.04
Pre-existing pain problem elsewhere						
No	403	42 (10.4%)	Reference			
Yes	20	4 (20.0%)	2.15 (0.69–6.73)	.26		
Inspired oxygen concentration ^b						
21%–40%	43	7 (16.3%)	Reference			
41%–60%	60	9 (15.0%)	1.28 (0.48–3.42)	.63		
>61%	106	14 (13.2%)	1.16 (0.47–2.87)	.75		

Values are n (%), mean ± standard deviation, or median (range).

^a Range of possible scores 0 (lowest level) to 21.


^b This analysis included only those patients receiving nitrous oxide-free anesthesia.

**Mais aucune étude
prospective pour N₂O et
PPSP...**

Magnésium

(Bloqueur « naturel »
des rec. NMDA au repos...)

NMDA receptors




Krystal et al, Pharmacol. Ther., 2003

Peri-operative intravenous administration of magnesium sulphate and postoperative pain: a meta-analysis

E. Albrecht,¹ K. R. Kirkham,¹ S. S. Liu² and R. Brull³

Anaesthesia 2012

Toronto, Canada




“ We conclude that peri-operative intravenous magnesium reduces opioid consumption, and to a lesser extent, pain scores, in the first 24h postoperatively, without any reported serious adverse effects”.


Changes in cerebrospinal fluid magnesium levels in patients undergoing spinal anaesthesia for hip arthroplasty: does intravenous infusion of magnesium sulphate make any difference? A prospective, randomized, controlled study

M. Mercieri^{1*}, R. A. De Blasi¹, S. Palmisani³, S. Forte¹, P. Cardelli², R. Romano⁴, G. Pinto¹ and R. Arcioni¹


British Journal of Anaesthesia 109 (2): 208–15 (2012)



A Changes in serum ionized and total [Mg] over time





B Changes in CSF ionized and total [Mg] over time



Pas de
delta
dans
CSF!!!

Gabapentine, Pregabalin





The Prevention of Chronic Postsurgical Pain Using Gabapentin and Pregabalin: A Combined Systematic Review and Meta-Analysis

AA 2012

Hance Clarke, MSc, MD, FRCPC,*†‡ Robert P. Bonin, PhD,§ Beverley A. Orser, MD, PhD, FRCPC,†‡ Marina Englesakis, BA MLIS,|| Duminda N. Wijeyesundera, MD, PhD, FRCPC,*†¶# and Joel Katz, PhD**

Identification:




Figure 1. Selection process for systematic review.

- 6 des études sur la **GABAPENTINE** ont démontré une réduction seulement modérée dans le développement des PPSP (pooled odds ratio [OR] 0.52; 95% confidence interval [CI], 0.27 to 0.98; $P = 0.04$),
- Les 2 études sur la **PREGABALINE** ont rapporté une grande réduction des PPSP (pooled OR 0.09; 95% CI, 0.02 to 0.79; $P = 0.007$),
- **CONCLUSIONS :** La présente métaanalyse supporte l'utilisation des gabapentinoïdes pour réduire les PPSP

Perioperative Gabapentinoids

Choice of Agent, Dose, Timing, and Effects on Chronic Postsurgical Pain

Peter C. Schmidt, M.D.,* Gabriela Ruchelli, B.A.,† Sean C. Mackey, M.D., Ph.D.,‡
Ian R. Carroll, M.D., M.S. Epi.§

It should now be generally accepted that the gabapentinoids are effective in reducing *immediate* postoperative pain and opioid consumption. The clinician should recognize that this has been better established for gabapentin than pregabalin. However, larger studies with both longer follow-up and improved patient retention will be needed to more definitively test the efficacy of these agents to reduce the emergence of *chronic* postsurgical pain. When more studies on both pregabalin and gabapentin have been done assessing the effect of the gabapentinoids on chronic pain, another meta-analysis should examine the strength of the body of evidence as a whole. However, the currently available data support the conclusion that such a preventative analgesic effect is likely.

Anesthesiology 2013; 119:1215-21

Table 3. Studies Finding an Effect on Prolonged Postoperative Pain

Authors	N	Surgery	Gabapentinoid Dose	Findings
Fassoulaki <i>et al.</i> ³⁵	60	Abdominal hysterectomy	Gabapentin 400 mg every 6 h beginning preoperatively and continuing for 5 days	Decreased incidence and intensity of pain at 1 month
Sen <i>et al.</i> ⁴³	60	Herniorrhaphy	Gabapentin 1,200 mg 1 h before surgery	Decreased pain scores at 1, 3, and 6 months
Sen <i>et al.</i> ⁴²	60	Abdominal hysterectomy	Gabapentin 1,200 mg 1 h before surgery	Decreased incidence of incisional pain at 1, 3, and 6 months
Brogly <i>et al.</i> ³¹	50	Thyroidectomy	Gabapentin 1,200 mg 2 h before surgery	Decreased incidence of neuro-pathic pain at 6 months
Amr and Yousef ³⁰	150	Mastectomy	Gabapentin 300 mg/day starting the night before surgery and continuing for 10 days	Decreased incidence of burning pain at 6 months
Fassoulaki <i>et al.</i> ³⁶	75	Breast surgery for cancer	Gabapentin 1,200 mg/day for 10 days after surgery	Decreased incidence of burning pain at 3 months
Buvanendran <i>et al.</i> ²⁶	240	Total knee arthroplasty	Pregabalin 300 mg 1–2 h before surgery and a 14-day taper after surgery	Decreased incidence of neuro-pathic pain at 3 and 6 months
Pesonen <i>et al.</i> ⁴¹	70	Cardiac surgery	Pregabalin 150 mg 1 h before surgery and 150 mg daily for 5 days	Decreased incidence of pain with movement at 3 months
Burke and Shorten ³²	40	Lumbar discectomy	Pregabalin 300 mg 90 min before surgery and 150 mg at 12 and 24 h after surgery	Decreased pain scores and improved function at 3 months

Table 4 Studies Finding No Effect on Prolonged Postoperative Pain

Authors	N	Surgery	Gabapentinoid Dose	Findings
Ucak <i>et al.</i> ⁴⁴	40	Coronary artery bypass graft	Gabapentin 1,200 mg before and for 2 days after surgery	No difference in pain scores at 1 and 3 months (all scores ≤ 1)
Clarke <i>et al.</i> ³³	126	Total hip arthroplasty	Gabapentin 600 mg 1–2 h before surgery or 600 mg immediately postoperatively	No difference in presence or severity of pain at 6 months
Moore <i>et al.</i> ³⁹	44	Cesarean section	Gabapentin 600 mg 1 h before surgery	No difference in persistent pain or abnormal wound sensation at 3 months
Nikolajsen <i>et al.</i> ⁴⁰	41	Lower limb amputation	Gabapentin titrated to 2,400 mg/day beginning on the first postoperative day and continuing for 30 days	No difference in phantom or stump pain at 3 and 6 months
Gianesello <i>et al.</i> ³⁷	60	Lumbar laminectomy and fusion	Pregabalin 300 mg 1 h before surgery for 2 days after surgery	No difference in pain scores at 3 months and 1 yr (quality of life measures improved at 3 months)
Kim <i>et al.</i> ³⁸	94	Endoscopic thyroidectomy	Pregabalin 150 mg 1 h before surgery and at 12 h after surgery	No difference in pain or hypoesthesia at 3 months
Fassoulaki <i>et al.</i> ³⁵	80	Abdominal hysterectomy or myomectomy	Pregabalin 150 mg every 8 h starting the afternoon before surgery and continuing 5 days	No difference in presence of pain, analgesic intake, or wound sensation at 1 and 3 months

Table 1. Dosage Adjustments for Renal Impairment

Creatinine Clearance, ml/min	Maximum Daily Pregabalin Dose, mg	Maximum Daily Gabapentin Dose, mg
≥60	600	3,600
30–60	300	1,400
15–30	150	700
15	75	300

Recommended doses :

	Pregabalin	Gabapentin	
At least 2 hours prior to surgery	300mg	1200mg	Consider dosing the night prior to surgery if clinical situation allows (e.g. inpatient)
Postoperative days 1-14	150mg	600mg	Monitor for excessive sedation, dizziness, or confusion
	150mg	600mg	
	150mg	600mg	

Lidocaine I.V.

Perioperative Intravenous Lidocaine Decreases the Incidence of Persistent Pain After Breast Surgery

Anca Grigoras, MD, Peter Lee, MD, Faisal Sattar, BSc, and George Shorten, PhD

Clin J Pain • Volume 28, Number 7, September 2012




FIGURE 1. The flow diagram of patients studied. PPSP indicates persistent postsurgical pain.

Immediately after orotracheal intubation, patients of the lidocaine group (L) received an IV bolus of lidocaine (1.5 mg/kg in 10 min) followed by a continuous IV infusion at 1.5 mg/kg/h. The infusion was stopped 60 minutes after skin closure. Patients in the control group (C) received an equivalent saline regimen. The anesthetist, surgeon, and nursing staff were all blinded to the group allocations.




TABLE 3. Postoperative Morphine Consumption

	Lidocaine Group (n = 17)	Control Group (n = 19)	<i>P</i>
Analgesia request in 24 h	13/17 (76.5%)	14/19 (73.3%)	0.849
Morphine 2 h	2.6 (± 2.5)	3.0 (± 3.8)	0.869
Morphine 4 h	0.5 (± 1.3)	1.4 (± 2.3)	0.179
Morphine 24 h	2.1 (± 5.1)	4.2 (± 10.3)	0.623
Morphine 2 d	0.3 (± 1.2)	3.1 (± 8.7)	0.310
Morphine 3 d	0.2 (± 0.7)	2.3 (± 5.7)	0.310
Morphine 4 d	0	0.5 (± 2.3)	0.344
Morphine 5 d	0	0	1.000
Morphine 6 d	0	0	1.000
Morphine 7 d	0	0	1.000

TABLE 4. Chronic Pain Assessment (Patients' Characteristics at 3 mo Follow-up)

	Lidocaine Group (n = 17)	Control Group (n = 19)	<i>P</i>
PPSP	2 (11.8%)	9 (47.4%)	0.031*
S-PRI	1.1 ($\pm$ 3.9)	1.4 ($\pm$ 3.2)	0.049*
A-PRI	0.1 ($\pm$ 0.5)	0.7 ($\pm$ 2.1)	0.196
T-PRI	1.2 ($\pm$ 4.4)	2.1 ($\pm$ 5.3)	0.039*
PPI-VAS	2.6 ($\pm$ 7.5)	14.6 ($\pm$ 22.5)	0.025*
Overall pain intensity	0.2 ($\pm$ 0.5)	0.9 ($\pm$ 1.4)	0.023*
HADS anxiety	5.4 ($\pm$ 4.9)	2.8 ($\pm$ 4.2)	0.108
HADS depression	5.4 ($\pm$ 4.4)	3.0 ($\pm$ 3.4)	0.079
PCS rumination	1.3 ($\pm$ 2.4)	1.7 ($\pm$ 3.8)	0.971
PCS magnification	1.1 ($\pm$ 2.5)	0.9 ($\pm$ 1.7)	0.719
PCS helplessness	1.5 ($\pm$ 3.1)	1.4 ($\pm$ 3.7)	0.580
PCS total	3.9 ($\pm$ 7.1)	4.0 ($\pm$ 9.1)	0.631
Required analgesia	1 (5.9%)	2 (10.5%)	1.000
Worse with movement	0	8 (42.1%)	0.003*
Interfere with activities	1 (5.9%)	5 (10.5%)	0.182
Hyperalgesia (cm)	0.2 ($\pm$ 0.8)	3.2 ($\pm$ 4.5)	0.002*

*Statistically significant difference.

Data are presented as mean $\pm$ SD or number of patients.

Extent of hyperalgesia is expressed as area of hyperalgesia (cm²) divided by length of surgical incision (cm).

A-PRI indicates affective pain rating index; HADS, Hospital Anxiety and Depression Scale; PCS, Pain Catastrophizing Scale; PPI-VAS, present pain intensity-visual analog scale; PPSP, persistent postsurgical pain; S-PRI, sensory pain rating index; T-PRI, total pain rating index.

CONCLUSION

Pre-op.	Intra-op.	Post-op.	Tardif Post-op.
Epidurale ou Bloc nerveux	Epidurale ou Bloc nerveux	Epidurale ou Bloc nerveux	

Du préop à aussi longtemps que possible...

P.O. pregabaline	i.v. ketamine i.v. lidocaine	i.v. ketamine 2 jours i.v. lidocaine P.O. pregabaline
Multimodale Pre-op Analgesie APAP NSAIDs ?	Multimodale Intra-op Analgesie i.v. APAP i.v. NSAIDs?	Multimodale Post-op Analgesie i.v. puis P.O. APAP i.v. puis P.O. NSAIDs? i.v. opioids (PCA morphine, HM...)

Merci pour votre attention!